Brainsway Ltd. (TASE:BRIN) today reported positive final results in a clinical trial of its Deep TMS (transcanial magnetic resonance) device for opening of the blood brain barrier in patients with malignant brain tumors. The treatment was found to temporarily, but significantly, open the blood brain barrier.
Brainsway said that the temporary opening of the blood brain barrier is important for the timing of delivery of current drug therapies, such as chemotherapies, and new therapies, in order to provide more focused delivery to improve their effectiveness.
The trial by Advanced Technologies Innovation Distribution srl at Ben Gurion University of the Negev and Sapienza University of Rome included 19 patients. Seven patients were dropped from the study due to technical problems, or because the tumors seen in the imaging were too small for analysis of the results. The control group comprises four persons without malignant brain tumors.
Deep TMS stimulation of the tumor and its environs resulted in temporary significant reduction in 10 of the 12 patients (83%) who completed the trial, in line with the results of the preclinical trial conducted by Ben Gurion University. The patients in the current trial suffer from malignant brain tumors (Glioblastoma Multiforme) which had been operated on at least a year before the trial. The results of the treatment were measured by MRI scans and special protocols developed by Ben Gurion University for measuring the opening of the blood brain barrier.
Brainsway's share price rose 7% in morning trading today to NIS 18.82, giving a market cap of NIS 222 million.
Published by Globes [online], Israel business news - www.globes-online.com - on February 19, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012